Related Experiment Video
Updated: Jun 12, 2025
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Utility of pembrolizumab for metastatic castrate resistant prostate cancer with MMR deficiency
Brian F Dinerman1, Andrew Skomra1, Iryna Dovirak2
1University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Department of Urology, Buffalo, NY, USA.
Abstract:
Molecular tumor profiling has become an important diagnostic for prostate cancer, allowing for personalized treatment regimens based on somatic and germline genetic information. We report a 67-year-old patient with metastatic castrate-resistant prostate cancer which was intermittently responsive to androgen-deprivation therapy, docetaxel, abiraterone, radium-223, Sipuleucel-T, and radiotherapy who ultimately demonstrated a remarkable and durable response to pembrolizumab. Our case report underlines the significance of early tumor molecular profiling in aggressive or atypical prostate cancer patients and exhibits the potential for a remarkable clinical response with immunotherapy in candidates with the appropriate tumor profiles.
Insights
Molecular tumor profiling aids personalized prostate cancer treatment. A patient with advanced prostate cancer showed a significant response to pembrolizumab immunotherapy, highlighting the value of early genetic testing.
Area of Science:
- Oncology
- Genetics
- Immunotherapy
Background:
- Molecular tumor profiling is crucial for personalized prostate cancer treatment.
- Metastatic castrate-resistant prostate cancer (mCRPC) presents treatment challenges.
- Genetic information guides therapeutic decisions in prostate cancer.
